Intradermal vaccination of dendritic cell-derived exosomes is superior to a subcutaneous one in the induction of antitumor immunity

Cancer Biotherapy and Radiopharmaceuticals

Volumn 21, Issue 2, 2006, Pages 146-154

  Hao, Siguo ^a   Ye, Zhenmin ^a   Yang, Jicheng ^b   Bai, Ou ^a   Xiang, Jim ^a,c  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b SOOCHOW UNIVERSITY   (China)

^c Saskatoon Cancer Center   (Canada)

Author keywords

Antitumor immunity; Cytotoxic T cells; Exosome; Vaccine

Indexed keywords

CANCER VACCINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; OVALBUMIN; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 4; T LYMPHOCYTE RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTING CELL; ARTICLE; BONE MARROW CELL; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DENDRITIC CELL; EXOSOME; FEMALE; FLOW CYTOMETRY; LYMPHOCYTE PROLIFERATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MEMBRANE VESICLE; MORTALITY; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR; TUMOR CELL CULTURE; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR MODEL; VACCINATION;

ANIMALS; CANCER VACCINES; CELL LINE, TUMOR; CELL MOVEMENT; DENDRITIC CELLS; FEMALE; IMMUNOTHERAPY; INJECTIONS, INTRADERMAL; INJECTIONS, SUBCUTANEOUS; MICE; MICE, INBRED C57BL; PHENOTYPE; THYMOMA; THYMUS NEOPLASMS; TRANSPORT VESICLES;

EID: 33744817657     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2006.21.146     Document Type: Article

References (37)

1. Nonacs R, Humborg C, Tam JP, et al. Mechanisms of mouse spleen dendritic cell function in the generation of influenza-specific, cytolytic T-lymphocytes. J Exp Med 1992;176:519.
2. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998;392:245.
3. Kawakami Y, Rosenberg SA. Immunobiology of human melanoma antigens MART-1 and gp100 and their use for immunogene therapy. Int Rev Immunol 1997;14:173.
4. Van den Eynde BJ, van der Bruggen P. T-cell-defined tumor antigens. Curr Opin Immunol 1997;9:684.
5. Zitvogel L, Mayordomo JI, Tjandrawan T, et al. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: Dependence on T-cells, B7 costimulation, and T helper cell 1-associated cytokines. J Exp Med 1996;183:87.
6. Celluzzi CM, Mayordomo JI, Storkus WJ, et al. Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity. J Exp Med 1996;183:283.
7. Nestle FO, Alijagic S, Gilliet M, et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 1998;4:328.
8. Hsu FJ, Benike C, Fagnoni F, et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 1996;2:52.
9. Murphy G, Tjoa B, Ragde H, et al. Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen. Prostate 1996;29:371.
10. Zitvogel L, Regnault A, Lozier A, et al. Eradication of established murine tumors using a novel cell-free vaccine: Dendritic cell-derived exosomes. Nat Med 1998; 4:594.
11. Guermonprez P, Saveanu L, Kleijmeer M, et al. ER-phagosome fusion defines an MHC class I cross-presentation compartment in dendritic cells. Nature 2003;425:397.
12. Kleijmeer MJ, Escola JM, UytdeHaag FG, et al. Antigen loading of MHC class I molecules in the endocytic tract. Traffic 2001;2:124.
13. Raposo G, Nijman HW, Stoorvogel W, et al. B-lymphocytes secrete antigen-presenting vesicles. J Exp Med 1996;183:1161.
14. Denzer K, Kleijmeer MJ, Heijnen HF, et al. Exosome: From internal vesicle of the multivesicular body to intercellular signaling device. J Cell Sci 2000;113(Pt 19):3365.
15. Escola JM, Kleijmeer MJ, Stoorvogel W, et al. Selective enrichment of tetraspan proteins on the internal vesicles of multivesicular endosomes and on exosomes secreted by human B-lymphocytes. J Biol Chem 1998;273:20121.
16. Clayton A, Court J, Navabi H, et al. Analysis of antigen presenting cell-derived exosomes, based on immunomagnetic isolation and flow cytometry. J Immunol Meth 2001;247:163.
17. Hsu DH, Paz P, Villaflor G, et al. Exosomes as a tumor vaccine: Enhancing potency through direct loading of antigenic peptides. J Immunother 2003;26:440.
18. Andre F, Chaput N, Schartz NE, et al. Exosomes as potent cell-free peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells. J Immunol 2004;172:2126.
19. Chaput N, Schartz NE, Andre F, et al. Exosomes as potent cell-free peptide-based vaccine. II. Exosomes in CpG adjuvants efficiently prime naive Tcl lymphocytes leading to tumor rejection. J Immunol 2004;172:2137.
20. Cho JA, Yeo DJ, Son HY, et al. Exosomes: A new delivery system for tumor antigens in cancer immunotherapy. Int J Cancer 2005;114:613.
21. + T-cells by dendritic cell-derived exosomes. Nat Immunol 2002;3:1156.
22. Vincent-Schneider H, Stumptner-Cuvelette P, Lankar D, et al. Exosomes bearing HLA-DR1 molecules need dendritic cells to efficiently stimulate specific T-cells. Int Immunol 2002;14:713.
23. Eggert AA, Schreurs MW, Boerman OC, et al. Biodistribution and vaccine efficiency of murine dendritic cells are dependent on the route of administration. Cancer Res 1999;59:3340.
24. Morse MA, Coleman RE, Akabani G, et al. Migration of human dendritic cells after injection in patients with metastatic malignancies. Cancer Res 1999;59:56.
25. Slingluff CL, Jr. Tumor antigens and tumor vaccines: Peptides as immunogens. Semin Surg Oncol 1996;12:446.
26. Li M, Davey GM, Sutherland RM, et al. Cell-associated ovalbumin is cross-presented much more efficiently than soluble ovalbumin in vivo. J Immunol 2001;166:6099.
27. Zhang W, Chen Z, Li F, et al. Tumour necrosis factor-alpha (TNF-alpha) transgene-expressing dendritic cells (DCs) undergo augmented cellular maturation and induce more robust T-cell activation and antitumour immunity than DCs generated in recombinant TNF-alpha. Immunology 2003;108:177.
28. Porgador A, Yewdell JW, Deng Y, et al. Localization, quantitation, and in situ detection of specific peptide-MHC class I complexes using a monoclonal antibody. Immunity 1997;6:715.
29. Chen Z, Dehm S, Bonham K, et al. DNA array and biological characterization of the impact of the maturation status of mouse dendritic cells on their phenotype and antitumor vaccination efficacy. Cell Immunol 2001;214:60.
30. Lyons AB, Parish CR. Determination of lymphocyte division by flow cytometry. J Immunol Meth 1994;17l:131.
31. Hao S, Bi X, Xu S, et al. Enhanced antitumor immunity derived from a novel vaccine of fusion hybrid between dendritic and engineered myeloma cells. Exp Oncol 2004;26:300.
32. + T-cell memory. Science 2002;297:2060.
33. Hwang I, Shen X, Sprent J. Direct stimulation of naïve T-cells by membrane vesicles from antigen-presenting cells: Distinct roles for CD54 and. B7 molecules. Proc Natl Acad Sci USA 2003;100:6670.
34. Andre F, Schartz NE, Movassagh M, et al. Malignant effusions and immunogenic tumour-derived exosomes. Lancet 2002;360:295.
35. Barratt-Boyes SM, Watkins SC, Finn OJ. In vivo migration of dendritic cells differentiated in vitro: A chimpanzee model. J Immunol 1997;158:4543.
36. Maloy KJ, Erdmann I, Basch V, et al. Intralymphatic immunization enhances DNA vaccination. Proc Natl Acad Sci USA 2001;98:3299.
37. Cella M, Sallusto F, Lanzavecchia A. Origin, maturation, and antigen presenting function of dendritic cells. Curr Opin Immunol 1997;9:10.